Identification of Histoplasma-Specific Peptides in Human Urine by Crockett, David K. et al.
Hindawi Publishing Corporation
International Journal of Peptides
Volume 2012, Article ID 621329, 4 pages
doi:10.1155/2012/621329
Research Article
Identiﬁcation of Histoplasma-Speciﬁc Peptidesin
HumanUrine
DavidK.Crockett,MarkM.Kushnir,Joann L.Cloud,
EdwardR.Ashwood,andAlanL.Rockwood
ARUP Institute for Clinical & Experimental Pathology, Department of Pathology, University of Utah, Salt Lake City, UT 84108, USA
Correspondence should be addressed to David K. Crockett, david.crockett@aruplab.com
Received 22 December 2011; Accepted 26 January 2012
Academic Editor: Suhn Hee Kim
Copyright © 2012 David K. Crockett et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Histoplasmosis is a severe dimorphic fungus infection, which is often diﬃcult to diagnose due to similarity in symptoms to other
diseases and lack of speciﬁc diagnostic tests. Urine samples from histoplasma-antigen-positive patients and appropriate controls
were prepared using various sample preparation strategies including immunoenrichment, ultraﬁltration, high-abundant protein
depletion, deglycosylation, reverse-phase fractions, and digest using various enzymes. Samples were then analyzed by nanospray
tandem mass spectrometry. Accurate mass TOF scans underwent molecular feature extraction and statistical analysis for unique
disease makers, and acquired MS/MS data were searched against known human and histoplasma proteins. In human urine, some
52 peptides from 37 Histoplasma proteins were identiﬁed with high conﬁdence. This is the ﬁrst report of identiﬁcation of a
large number of Histoplasma-speciﬁc peptides from immunoassay-positive patient samples using tandem mass spectrometry and
bioinformatics techniques. These ﬁndings may lead to novel diagnostic markers for histoplasmosis in human urine.
1.Introduction
Infection and disease caused by pathogenic and oppor-
tunistic fungi has been increasing over the past decade.
One widespread and severe fungal disease, histoplasmosis,
is caused by the dimorphic fungus Histoplasma capsulatum.
The H. capsulatum mycelial phase may be inhaled by mam-
mals to cause pulmonary disease [1]. Disease progression
then occurs as the fungus transforms to yeast phase and
disseminates to other parts of the body [2]. While most
infections are mild, it can lead to rapid progression and life
threatening symptoms for individuals with weak immune
systems such as elderly, infants, HIV, and cancer patients
or transplant recipients [3]. Furthermore, once infected, a
latent infection may also be reactivated. Current laboratory
testing for histoplasmosis does not provide adequate clinical
sensitivity and speciﬁcity for accurate diagnosis of this
infection. Antigen cross reactivity with other fungi species
can be especially troublesome [4, 5].
Although progress has been made in understanding
the pathogen-host interaction [6, 7], there are currently
no known biomarkers of histoplasma infection, whereby
molecular or chemical structures have been clearly deﬁned.
Incomplete genomes and/or databases for either protein
or nonprotein compounds from Histoplasma have been a
signiﬁcant limitation of the work to date. This limitation
has been improved due to recent eﬀorts of the Human
Microbiome Project hosted by the Genome Center at Wash-
ingtonUniversityandtheBroadInstitute[8,9].Theresulting
genome and protein entries into public databases (such
as NCBI) allow proteomics-based research to now move
forwardinameaningfulway.Thisstudyutilizedcomparative
LC-MS/MS analysis of urine specimens from infected and
noninfected patients to identify several potential protein
and peptide markers speciﬁc to H. capsulatum infection in
human urine.
2.MaterialsandMethods
Samples utilized in the study were unused aliquots of human
urine samples referred for clinical laboratory testing at2 International Journal of Peptides
Table 1: Histoplasma-speciﬁc peptides identiﬁed from infected patient urine.
NCBI Protein Peptide BLAST ind.
accession description sequence E-value obs.†
154275270 polyubiquitin LDVESADTIDAVK 0.006 5
TLSDYNIQKESTLHLVLR 3e−08 4
MQIFVK 1107 4
IQDKEGIPPDQQRLIFAGK 2e−09 3
225554709 leucyl-tRNA synthetase IDLLAVDK 141 4
TVPSIFSSPWPDPLLSSR 2e−08 3
NSSTISSPPR 3.8 3
240281880 conserved hypothetical protein NPKSRPQHLQTATTNGR 4e−07 3
SLEILRQR 78 3
240277865 DUF500 and SH3 domain-containing protein NAEAAGAASTKGVAGVFSYSK 3e−09 3
IGDRTGIFPSNYVDASNL 3e−08 3
240280678 5-oxoprolinase GITGEYIHILVKPDMEK 5e−08 3
150412285 mannosyl-oligosaccharide 1,2-alpha- mannosidase NHTSISVQDRDPPIR 9e−06 3
150408441 ADP-ribosylation factor ITHSWVLQSLTRRAW 2e−06 3
239613150 predicted protein KQTNYVSGLFRNSRT 2e−05 3
240276397 histone transcription regulator slm9 AISDLSWSPDGK 0.019 3
SWSPDG 2675 3
150406597 hypothetical protein HCAG 00002 GWDQTGSNGANL 0.019 3
240273359 glycogen debranching enzyme RLGLSALIRE 3.8 3
150408639 predicted protein NLLTCMSR 24 3
240274939 ubiquitin-activating enzyme NSFVNLALPFFSFIDPIASPMDK 1e−13 2
LNNSEPR 535 3
240281152 conserved hypothetical protein RQFVDSLSEGLGEQGKG 2e−06 3
239614048 TdiA RGEHKYDPVVTLQPFGNKA 2e−92
240273135 xaa-proaminopeptidase SKHQHFVGLSFDTISST 5e−07 2
DIEFLIPIQCSILSERR 5e−08 2
LDALRVPLTHLLAVR 5e−05 2
240276009 priB RSKERSWLMLFVYDRS 1e−07 2
150411212 methionine sulfoxide reductase msrB YFDSIPGAVTRKEDR 1e−05 2
239611175 predicted protein TVIVITRRSLEPAR 3e−04 2
225555719 SAM and PH domain-containing protein NWMRELMLARALK 1e−04 2
348156 YPS-3 yeast phase-speciﬁc protein PAPFCGTCNPISGK 1e−04 2
150409767 predicted protein KLDGAVPFKVQTRM 1e−04 2
239609148 phenol monooxygenase MKPFTEEETIK 0.026 2
150407363 predicted protein KCPTLSPENKN 0.084 2
154280483 predicted protein LLFVGSNSAPGR 0.084 2
TLPDDHILQEAK 0.011 2
150411980 conserved hypothetical protein KLNMRVARWRE 0.011 2
225561657 conserved hypothetical protein ISITDPANDR 1.2 2
239613737 cysteine synthase B RVATSILRA 36 2
240275767 conserved hypothetical protein LSIQATLIR 20 2
LSIQA 75910 2
240276203 DNA binding protein URE-B1 AENTAESPESEDVKVK 9e−06 1
ADPFATTPSKPR0 0.026 1
150414072 predicted protein MFYFDSEFVGPPR 1e−04 1
LLWGGAQQER 0.66 1
150412949 conserved hypothetical protein RFSIKSCLFPHAKK 1e−04 1
150412547 predicted protein RFLQPGDLVVLKS 0.003 1International Journal of Peptides 3
Table 1: Continued.
NCBI Protein Peptide BLAST ind.
accession description sequence E-value obs.†
150413459 predicted protein KLSTLVGALATRN 0.019 1
240274117 pre-mRNA splicing factor RVAEEMRCKV 0.27 1
154282923 2-isopropylmalate synthase ACTLAAEPDR 1.6 1
239610650 glycerol:H+ symporter KAVLASEPRT 5.2 1
†Number of times peptide(s) identiﬁed in independent experiments.
ARUP Laboratories (Salt Lake City, UT). Initial experiments
included samples (n = 14) positive for histoplasma antigen
(HAG) retrieved from samples submitted for routine clinical
testing using an existing polyclonal enzyme immunoas-
say developed and validated by ARUP Laboratories using
analyte-speciﬁc reagents (ImmunoMycologics, Inc., Nor-
man, OK). Negative control samples (n = 14) were urine
samples from individuals without histoplasma antigenuria.
The study was approved by the Institutional Review Board of
the University of Utah.
The following methodologies were used alone or in
combination for sample preparation including immuno-
enrichment (Immuno-Mycologics, Inc., Norman, OK),
glyco-enrichment, SDS-PAGE gel separation, fractionation
by molecular weight using ultraﬁltration (Amicon Ultra-
4, Millipore, Billerica, MA), high-abundant protein deple-
tion (Agilent Technologies, Santa Clara, CA, Part #5185–
5984) [10], deglycosylation (EDEGLY, Sigma-Aldrich, St.
Louis, MO), reverse-phase fractions, and digestion using
trypsin, glutamic C, or proteinase K (Princeton Separa-
tions, Adelphia, NJ). Experiments for discovery and valida-
tion of Histoplasma urine peptides were performed using
nanoESI—tandem mass spectrometry (Agilent 6510 QTOF
and AB/Sciex 4000 QTrap). Data was acquired (MassHunter
3.0 and Analyst 1.5) using replicate TOF scans as well as
Auto MS/MS or information-dependent acquisition (IDA)
MS/MS experiments. Replicate analysis was also performed
using mass range partitions for precursor isolation of 400–
600, 600–800, and 800–1600m/z.
Accurate mass TOF scans were processed using
MassHunter software (Agilent) for molecular feature extrac-
tion by retention time, mass-to-charge ratio, and integrated
peak area. Files with molecular features (.mhd ﬁle format)
corresponding to each analyzed sample were then uploaded
into GeneSpringMS (Agilent) for further statistical analysis
consisting of statistical ﬁltering by normalized peak abun-
dances, analysis of variance (ANOVA) and fold change (>2)
between disease and control groups, signiﬁcance testing, and
unsupervised condition tree clustering to identify candidate
features that were statistically signiﬁcant and unique to the
disease data set. Acquired MS/MS data ﬁles were searched
using Mascot or Spectrum Mill (Agilent) against a combined
human/histoplasma protein electronic fasta database (April
2011 NCBI download), and the results were evaluated.
Lastly, pooled samples in multiple independent experi-
ments (n = 6) and additional individual samples (disease,
n = 50 and control, n = 110) were used to validate potential
biomarkers of HAG. Targeted MS/MS and extracted ion
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Figure 1:Rapidgrowthofelectronicfastadatabaseentriesavailable
for download at NCBI for Histoplasma proteins over last 7 years.
chromatograms (EIC) were also used to manually verify
peptide targets. Potential nonhuman peptides identiﬁed in
these experiments were further conﬁrmed against the full
NCBI nonredundant database using protein-protein BLAST
(pBLAST).
3. Results and Discussion
Although high-quality spectra were acquired during initial
experiments, early searchresults werefrustratedaselectronic
databases contained less than 250 protein entries for Histo-
plasma. Experiments during 2006 and 2007 identiﬁed only
5 potential peptides belonging to Histoplasma.L a t e re x p e r i -
ments (2008-2009) yielded more promising results, but only
an additional 14 peptides conﬁdently identiﬁed. To better
evaluate the newly added fungal sequences recently made
public,alloriginaldataﬁles(2006–2010)werecombinedand
the MS/MS search repeated using the latest available NCBI
electronicproteinfastaentries(n =19,178).Importantly,this
increased number of protein entries led to an approximate
10-fold increase in the number of high-quality spectra
matching Histoplasma-speciﬁc peptides. Further indepen-
dentexperimentswereperformedtoconﬁrminitial ﬁndings.
This remarkable growth of electronic fasta database entries
for Histoplasma proteins over the last 7 years, as available for
download at NCBI is shown in Figure 1.
Histoplasma-speciﬁc peptides identiﬁed in this study are
summarized in Table 1, where entries are ranked by the
number of independent observations and BLAST score indi-
cating“uniqueness”ofthepeptides.Intotal,52peptideswere
identiﬁed with a high degree of conﬁdence, which belongs4 International Journal of Peptides
to 37 known and predicted Histoplasma proteins. Measuring
one or more of these markers in patient samples may be
potentially useful for diagnostic testing of histoplasmosis.
4. Conclusions
Diagnosis and management of invasive fungal disease
remains a major health problem, both in this country and
worldwide. The ability to deﬁnitively diagnose histoplasmo-
sis has become even more important due to the increasing
number of patients with weakened immune systems who are
susceptible to this life threatening disease, yet the laboratory
tests for this disease are far from adequate.
Obviously, since fungal proteins and peptides are not
expected to be present in urine from noninfected patients,
studies similar to this represent a rich source of poten-
tial and novel targets for clinical diagnostic testing. The
multiple and independent experiments with exhaustive
s a m p l ep r e p a r a t i o nr e p o r t e dh e r eh a v er e s u l t e di nau n i q u e
data set representing the urine proteome associated with
histoplasma antigenuria. Importantly, data ﬁles have been
uploaded to the Proteome Commons Tranche repository
(http://proteomecommons.org/) as a Histoplasma group
project and are publically available as of May 2011.
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